Pasithea Therapeutics Corp. (KTTA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+2031.8%

$7.85

vs $0.37 price

Levered DCF

$7.85

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

1.38

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
P/E	-0.44×	-0.25×	-0.57×	-1.24×	-8.43×	-1,198.65×
P/B	0.16×	0.23×	0.39×	0.38×	0.36×	203.23×
P/S	0×	0×	0×	0×	1,222.7×	0×
EV / EBITDA	2.28×	0.26×	0.47×	1.4×	15.91×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	-14.7%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	-29925.7%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	-14430.5%	0.0%
Current ratio	11.35×	6.58×	6.34×	18.15×	119.17×	37.55×
Debt / equity	0×	0×	0×	0.01×	0×	0×
Interest coverage	0×	0×	0×	-123,421.28×	-8,872.86×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Return on equity	-37.0%	-94.1%	-68.2%	-32.8%	-4.2%	-25.5%
Return on invested capital	-37.7%	-95.4%	-67.8%	-29.0%	-8.5%	-25.5%
Return on assets	-33.9%	-86.6%	-61.1%	-30.8%	-4.1%	-24.8%
Free cash flow yield	-167.7%	-403.3%	-148.3%	-85.1%	-17.4%	-0.1%
Earnings yield	-225.2%	-402.7%	-175.9%	-86.0%	-11.8%	-0.1%
Enterprise value	-$46.1M	-$3.5M	-$7.2M	-$16.4M	-$34.6M	$48.8M
Net debt / EBITDA	2.73×	0.51×	1.06×	2.78×	24.39×	0×
Cash conversion cycle (days)	0	0	0	-106,146	0	0